Corteva

CTVA · NYSE

$12.90+$0.0988 (+0.77%)TodayMarket closed · Oct 21, 4:14 AM ET

Prev close $12.80

CTVA analyst rating

BuyConsensus of 16 analysts over the last 12 months. 88% rate it a buy.

Strong buy0
Buy14
Hold2
Underperform0
Sell0

12-month price target · 24 analysts

Average $90.37 (+600.5% upside)

Low: $19.19
Now: $12.90
High: $108.15

Upgrades and downgrades

The latest rating actions, newest first

CTVA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Maintains	Neutral	$90.00 → $15.00	49%
Keybanc	Oct 7, 2026	Upgrade	Sector Weight → Overweight	$17.00	30%
JP Morgan	Oct 6, 2026	Upgrade	Neutral → Overweight	$83.00 → $19.00	57%
Argus Research	Sep 18, 2026	Maintains	Buy	$91.00	67%
Citigroup	Sep 17, 2026	Maintains	Neutral	$86.00 → $91.00	53%
BMO Capital	Sep 16, 2026	Maintains	Outperform	$100.00 → $95.00	45%
UBS	Sep 16, 2026	Maintains	Neutral	$85.00 → $90.00	49%
RBC Capital	Sep 16, 2026	Maintains	Outperform	$103.00	46%
Keybanc	Sep 11, 2026	Initiates	Sector Weight	—	30%
UBS	Aug 18, 2026	Maintains	Neutral	$89.00 → $85.00	49%

The case for and against

Updated Oct 16, 2026

Bull case

Corteva is well positioned by its attractive valuation, trading around 6.5x-6.7x EV/EBITDA and implying roughly a 10% unlevered FCF yield, while ending 2026 with an expected $0.5B net cash position that supports buybacks and M&A. Its outlook is anchored by a solid pipeline, strong biologics franchise, and new products expected to add about $800M in annual revenues by 2029 versus 2026, alongside another $200M of cost savings that could lift EBITDA toward the top of management’s $1.45B-$1.65B target. Growth is further supported by improving farmer economics and a geographically diversified crop protection business, with North America generating nearly 40% of revenue and Latin America over 30%, giving the company multiple channels for earnings expansion.

Bear case

Corteva is facing a weak fundamental setup because crop chemicals remain under persistent deflationary and generic pressure, with management itself assuming a 1% annual price decline during the 2027-2029 period and the market still expected to decline 4-5% in 2026. Its narrower post-spin product portfolio may reduce negotiating leverage with large customers, especially in Brazil, while weaker farm economics, softer crop prices, and destocking threaten demand for crop protection and seed inputs. Although the company could still generate about $400M in post-dividend FCF in 2027 and buy back shares, legal settlement outflows and the risk of slower pipeline monetization or poor capital deployment leave the downside case intact.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.